Sugi Predict

Sugi Predict / Compounds / SCHEMBL935492

SCHEMBL935492

SCHEMBL935492

CCCCCCCCN(CCCCCCCC)C(=O)COCC(=O)N(CCCCCCCC)CCCCCCCC

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.45
▸ CA1 P00915 3/20 0.45
▸ CA9 Q16790 3/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CES2 O00748 5/20 0.44
▸ MGLL Q99685 1/20 0.41
▸ ZDHHC20 Q5W0Z9 2/20 0.41
▸ ZDHHC2 Q9UIJ5 1/20 0.41
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ DNM1 Q05193 2/20 0.39
▸ KDM5A P29375 1/20 0.38
▸ CES1 P23141 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758628 1.00 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL936147 1.00 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL26764119 1.00 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL24178779 1.00 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL3268168 1.00 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL24178687 1.00 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL29758625 0.98 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL21481160 0.98 CA12 (0.45) CA12CA1CA9CA2CES2
SCHEMBL23039655 0.98 CA12 (0.43) CA12CA1CA9CA2CES2
SCHEMBL24178778 0.96 CA12 (0.42) CA12CA1CA9CA2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570539-B2 Systems and methods for generating radionuclides PERSPECTIVE THERAPEUTICS, INC. (US) 2026-03-10 — — US claimed
US-20260008686-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES PERSPECTIVE THERAPEUTICS INC (US) 2026-01-08 — — US claimed
US-20250368525-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES PERSPECTIVE THERAPEUTICS INC (US) 2025-12-04 — — US claimed
US-20250372274-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES PERSPECTIVE THERAPEUTICS INC (US) 2025-12-04 — — US claimed
US-20250197345-A1 SYNTHESIS OF DIGLYCOLAMIDES UNITED STATES DEPARTMENT OF ENERGY 2025-06-19 — — US claimed
EP-4568784-A2 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES Perspective Therapeutics, Inc. (US) 2025-06-18 — — EP claimed
WO-2025123017-A2 METHOD AND SYSTEM FOR THE CONCENTRATION OF RADIUM AND ACTINIUM FROM DILUTE SOLUTIONS TERRAPOWER ISOTOPES, LLC (US) 2025-06-12 — — WO claimed
WO-2025102429-A1 METHOD AND DEVICE FOR RECOVERING ENRICHED 176YB GENERATED DURING PREPARATION PROCESS OF CARRIER-FREE 177LU 中国核动力研究设计院 2025-05-22 — — WO claimed
CN-115627354-B Method and system for separating strontium ions and calcium ions in high-level solution 中核四0四有限公司 2025-05-13 — — CN claimed
CN-118724344-B Method for recycling heavy metal ions from strongly acidic nuclear wastewater 四川长晏科技有限公司 2025-04-11 — — CN claimed
US-8354085-B1 Actinide and lanthanide separation process (ALSEP) U.S. DEPARTMENT OF ENERGY (US) 2013-01-15 — — US claimed
US-20110002823-A1 Pooled Separation of Actinides froma Highly Acidic Aqueous Phase Using a Solvating Extractant in a Salting-out Medium COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2011-01-06 — — US claimed
EP-2095372-B1 GROUPED SEPARATION OF ACTINIDES FROM A HIGHLY ACIDIC AQUEOUS COMPOSITION A SOLVATING EXTRACTANT IN A SALTING MEDIUM COMMISSARIAT ENERGIE ATOMIQUE (FR) 2010-03-17 — — EP claimed
US-7553461-B2 Multivalent metal ion extraction using diglycolamide-coated particles PG RESEARCH FOUNDATION, INC. (US) 2009-06-30 — — US claimed
US-20070163957-A1 MULTIVALENT METAL ION EXTRACTION USING DIGLYCOLAMIDE-COATED PARTICLES PG RESEARCH FOUNDATION, INC. 2007-07-19 — — US claimed
US-20070131618-A1 MULTIVALENT METAL ION EXTRACTION USING DIGLYCOLAMIDE-COATED PARTICLES PG RESEARCH FOUNDATION, INC. 2007-06-14 — — US claimed
US-20070065352-A1 PROCESS FOR RADIOISOTOPE RECOVERY AND SYSTEM FOR IMPLEMENTING SAME BATTELLE ENERGY ALLIANCE, LLC (US) 2007-03-22 — — US claimed
US-7157061-B2 Process for radioisotope recovery and system for implementing same BATTELLE ENERGY ALLIANCE, LLC (US) 2007-01-02 — — US claimed
US-20060153760-A1 Process for radioisotope recovery and system for implementing same BATTELLE ENERGY ALLIANCE, LLC 2006-07-13 — — US claimed
US-20040062695-A1 Multivalent metal ion extraction using diglycolamide-coated particles PG RESEARCH FOUNDATION, INC. 2004-04-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570539-B2 Systems and methods for generating radionuclides PSMA4, PSMA2, PSMA1 CA12 795/4885CA1 777/4885CA9 2333/4885
US-20250197345-A1 SYNTHESIS OF DIGLYCOLAMIDES RPN2, FUT6, RPN1 CA12 212/4885CA1 328/4885CA9 214/4885
US-20260008686-A1 SYSTEMS AND METHODS FOR GENERATING RADIONUCLIDES RBX1, LIN28A, CBX4 CA12 536/4885CA1 761/4885CA9 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.